Login to Your Account

Clinic Roundup

Thursday, July 28, 2011
Keryx Biopharmaceuticals Inc., of New York, and Aeterna Zentaris Inc., of Quebec City, completed enrollment in the pivotal Phase III trial of PI3K/Akt inhibitor perifosine (KRX-0401) plus Xeloda (capecitabine, Roche AG) for colorectal cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription